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Abstract: Cachexia and muscle wasting are frequently observed in heart failure patients. 
Cachexia is a predictor of reduced survival, independent of important parameters such as age, 
heart failure functional class, and functional capacity. Muscle and fat wasting can also predict 
adverse outcome during cardiac failure. Only more recently were these conditions defined in 
International Consensus. Considering that heart failure is an inflammatory disease, cardiac 
cachexia has been diagnosed by finding a body weight loss .5%, in the absence of other dis-
eases and independent of other criteria. Muscle wasting has been defined as lean appendicular 
mass corrected for height squared of 2 standard deviations or more below the mean for healthy 
individuals between 20 years and 30 years old from the same ethnic group. The etiology of 
heart failure-associated cachexia and muscle wasting is multifactorial, and the underlying 
physiopathological mechanisms are not completely understood. The most important factors 
are reduced food intake, gastrointestinal alterations, immunological activation, neurohormonal 
abnormalities, and an imbalance between anabolic and catabolic processes. Cachexia and muscle 
wasting have clinical consequences in several organs and systems including the gastrointestinal 
and erythropoietic systems, and the heart, previously affected by the primary disease. We hope 
that a better understanding of the mechanisms involved in their physiopathology will allow the 
development of pharmacological and nonpharmacological therapies to effectively prevent and 
treat heart failure-induced cachexia and muscle wasting before significant body weight and 
muscle wasting occurs.
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Introduction
Heart failure is a complex clinical syndrome in which damage to the heart or increased 
myocardial stress activates a systemic response that adversely affects cardiac struc-
tures and function over time.1 In the past few decades with a better understanding of 
heart failure physiopathology, it has become clear that pathological changes not only 
involve the cardiovascular system but also the renal, neuroendocrine, immune, mus-
culoskeletal, hematological, and gastrointestinal systems, as well as nutritional state. 
Several studies have been performed to elucidate the physiopathology of systemic 
complications in heart failure and establish therapeutic measures to improve quality 
of life and increase survival. These include studies on heart failure-associated cachexia 
and muscle wasting. In this review, we present a definition, the physiopathology, and 
clinical consequences of cardiac cachexia and muscle wasting.
Cachexia is a strong predictive factor for reduced survival in heart failure, inde-
pendent of important variables such as age, functional class, ejection fraction, and Research Reports in Clinical Cardiology 2014:5 submit your manuscript | www.dovepress.com
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physical capacity.2,3 The importance of cachexia in prognosis 
was reinforced after the description of reverse epidemiology 
of obesity in heart failure. In healthy individuals, increased 
body mass index is associated with an increased risk of 
developing cardiovascular disease. However, body mass 
index positively correlates with survival in heart failure 
patients.4,5 In a large meta-analysis of nine observational stud-
ies, Oreopoulus et al6 established that mortality rates from all 
causes and cardiovascular disease are reduced in overweight 
and obese heart failure patients. The mechanisms responsible 
for this obesity paradox in heart failure are not completely 
clear.7 As for cachexia, muscle wasting has been recently 
associated with parameters that indicate poor prognosis, 
such as reduced exercise capacity, muscle strength, and total 
peak oxygen consumption.8 Despite being known for a long 
time that severe body weight loss is associated with poor 
outcomes in several diseases, the mechanisms responsible 
for cachexia-induced death are not completely clear.9
Definition of cachexia  
and muscle wasting
Although cachexia is characterized by body weight loss and 
muscle wasting by a reduction in muscle mass without body 
weight loss,10,11 definition of these terms has evolved over 
time. The term “cachexia” originates from the Greek and 
means “bad condition”. Some patients present with such 
intense body weight loss that cachexia diagnosis is plainly 
evident. However, it is often difficult to diagnose cachexia 
in heart failure patients, as edema increases body weight 
and interferes with the evaluation of other anthropometric 
  measurements. Furthermore, it may be difficult to interpret 
results from nutritional biomarkers and estimate body compo-
sition through bioelectrical impedance analysis, particularly 
when body water is increased.12,13
Due to its influence on heart failure prognosis, it is 
important to have a specific simple definition of cachexia 
so that physicians can easily recognize the problem. 
However, cardiac cachexia has already had different 
definitions. In 1997, Anker et al14 proposed that, in heart 
failure patients, cachexia should be diagnosed when non-
intentional edema-free body weight loss was .7.5% of 
usual weight in the absence of hyperthyroidism or neo-
plastic and infectious diseases. Body weight loss should 
have occurred in a period longer than 6 months. Weight 
loss in shorter periods can also be due to heart failure, 
but other causes such as neoplastic or infectious diseases 
should be investigated. Later, the same authors observed 
that less intense body weight loss is already associated to 
worsening prognosis and proposed that a 6% body weight 
loss should be enough to characterize cardiac cachexia.15 
In 2006,   during the Cachexia Consensus Conference,16 
cachexia was defined as at least 5% edema-free body 
weight loss in the previous 12 months (or a body mass 
index ,20 kg/m2) in patients with chronic illness and at 
least three of the following clinical or laboratory criteria: 
decreased muscle strength, fatigue, anorexia, low fat-free 
mass index, and abnormal biochemistry characterized 
by increased inflammatory markers (C-reactive protein, 
interleukin [IL]-6), anemia (Hb ,12 g/dL), or low serum 
albumin (,3.2 g/dL). It should be pointed out that cachexia 
differs from malnutrition or anorexia, conditions that dif-
ferently from cachexia can easily be reversed with adequate 
nutrition.16 As heart failure is considered an inflammatory 
disease, cardiac cachexia has been diagnosed when body 
weight loss is .5% independent of other criteria.17,18
Body weight loss leads to skeletal muscle loss and vice 
versa. However, isolated skeletal muscle loss can also be 
observed during heart failure. Chronic disease-associated 
muscle loss has been preferably called muscle wasting as 
the term “sarcopenia” usually refers to healthy age-related 
muscle loss.8 Differently from cachexia, muscle-wasting 
diagnosis depends on laboratory investigation. Dual-energy 
X-ray absorptiometry has been used to accurately evaluate 
body composition and estimate total, lean, and fat mass.8,13 
However, although expensive, computed tomography, and 
magnetic resonance imaging are the gold standard for 
muscle mass assessment. The definition of muscle wast-
ing has recently been established as lean appendicular 
mass corrected for height squared of 2 or more standard 
deviations below the mean of healthy persons between 
20 years and 30 years of age of the same ethnic group.19 
Muscle wasting can also be suggested by a poor physical 
performance observed in different evaluation methods 
such as a 6-minute walk, handgrip strength, gait speed, or 
spiroergometry.13
Epidemiology
By defining cachexia as a body weight loss $6%, Anker 
et al15 observed that 34% of heart failure outpatients devel-
oped cachexia during 48 months of follow-up. Post hoc 
analyses of several heart failure trials have reported a preva-
lence of edema-free weight loss ranging from 8% to 42%.14,20 
More recently, in optimally treated nondiabetic outpatients, 
cachexia (body weight loss .5%) was observed in 10.5%.17 
Muscle-wasting prevalence has received less characteriza-
tion in literature. Using the definition of muscle wasting Research Reports in Clinical Cardiology 2014:5 submit your manuscript | www.dovepress.com
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mentioned earlier, this condition was recently observed in 
19.5% of patients with stable chronic heart failure.8
Physiopathology of heart  
failure-induced cachexia
The etiology of heart failure-associated cachexia and muscle 
wasting is multifactorial, and the underlying physiopathologi-
cal mechanisms are not completely understood. Although 
these mechanisms can differentially affect cachexia and 
muscle wasting, we present here the main factors responsible 
for the development of both conditions.
Imbalance between anabolic  
and catabolic processes
Skeletal muscle abnormalities are well established in heart 
failure and contribute to early dyspnea and fatigue dur-
ing physical activity.21–23 Maintenance of skeletal muscle 
mass depends on a delicate balance between anabolic and 
catabolic factors. Anabolic and catabolic process imbalance 
has gained increasing importance in the physiopathology 
of heart failure-induced cachexia and muscle wasting.24,25 
Enhanced proteolysis is the most consistent finding, whereas 
there is limited evidence for reduced protein synthesis.26 The 
  following major proteolytic pathways can be found in skel-
etal muscle: lysosomal, Ca2+ dependent, caspase dependent, 
and ubiquitin–proteasome dependent.27 One of the most 
important pathways responsible for intracellular degrada-
tion of striated muscle proteins is the ubiquitin–proteasome 
system.28–30 During ubiquitination, damaged cytosolic pro-
teins are linked to ubiquitin molecules and targeted toward 
the proteasome, where they are cleaved into short peptides 
and aminoacids.31
In heart failure, immunological and neurohormonal 
activation, as well as increased reactive oxygen species 
levels, stimulate nuclear factor-κB, which activates the 
ubiquitin proteasome system.13,27 In fact, components of the 
ubiquitin–proteasome system such as the muscle-specific 
E3 ligase muscle ring finger 1 were shown to be stimulated 
by proinflammatory cytokines and increased in skeletal 
muscle during heart failure.13,31 The ubiquitin–proteasome 
system can also be stimulated by myostatin and inhibited 
by   follistatin. Myostatin modulates muscle growth by act-
ing as a negative regulator of muscle bulk, and follistatin 
is a potent antagonist of myostatin. During pathological 
loading of the heart, the myocardium produces and secretes 
myostatin into circulation where it reaches skeletal muscles 
and inhibits their growth.32 We have observed in heart fail-
ure rats that muscle atrophy was combined with changes in 
myostatin/follistatin expression.22,33 Muscle disuse by bed 
rest can also contribute to protein catabolism.26
The most important consequence of increased protein 
degradation is a reduction in myocyte cross-sectional area 
and muscle mass, which contributes to a reduction in physi-
cal performance and daily living activities.21,34–38 As well 
as by increased proteolysis, reduced muscle mass can also 
be caused by apoptosis or necrosis.35,38,39 During several 
pathological conditions, muscle loss is not homogeneous 
and can involve predominantly slow type 1 or fast type 2 
muscle fibers.40 Also in heart failure, muscle loss pattern 
depends on experimental model, and both a slow-to-fast and 
a   fast-to-slow fiber-type shift has been described.33,41
Recently, Callahan and Toth26 suggested that increased 
proteolysis and reduced protein synthesis mainly occur dur-
ing disease exacerbation and hospitalization due to increased 
inflammatory and neurohormonal activation. As anabolic 
pathways are probably insufficient to recover muscle size 
and function to prehospitalization levels, efforts to prevent 
disease exacerbation should be emphasized.26
Finally, it has been showed that increased catabolism 
not only occurs in skeletal muscle but also in adipose 
tissue.42,43
Neurohormonal alterations
During cardiac failure, neurohormonal activation is related to 
several deleterious cardiac and systemic effects. Heart failure 
patients with cachexia present increased plasma concentrations 
of noradrenaline, epinephrine, cortisol, and aldosterone than 
healthy individuals or heart failure patients without cachexia, 
suggesting that systemic neurohormonal activation is involved 
in the physiopathology of cachexia.2,3 Clinical trials have 
shown that angiotensin-converting enzyme inhibitors15 and 
β-blockers44 reduce the probability of weight loss. In in vitro 
studies, angiotensin II (AII), aldosterone, and catecholamines 
induce inflammatory cell activation and cytokine synthesis.45–47 
Adrenergic stimulation may increase resting energy expendi-
ture and induce vasoconstriction, impairing intestinal perfu-
sion and bacterial translocation.27,48 Experimental studies have 
shown that AII can contribute to muscle wasting by increasing 
protein breakdown, reducing protein synthesis, and inhibiting 
muscle regenerative processes.28,49
More recently, the role of neurohormonal activation has 
also been evaluated in noncardiac cachexia. In liver cancer 
rats, β-blocker or aldosterone antagonism has increased sur-
vival and improved cancer-induced cardiac dysfunction.50
Other hormonal changes can also be involved in cachexia 
and muscle wasting. Heart failure patients can present a Research Reports in Clinical Cardiology 2014:5 submit your manuscript | www.dovepress.com
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state of growth hormone resistance. As a consequence, 
insulin growth factor (IGF)-1, which stimulates protein 
synthesis, myoblast differentiation, and muscle growth, is 
decreased.51–53 IGF-1 levels can also be downregulated by AII 
stimulation.27 IGF-1, in turn, prevents AII-induced skeletal 
muscle wasting through an Akt/forkhead box O–dependent 
pathway.54 N-terminal fragment levels of prohormone brain-
type natriuretic peptide (NT-proBNP), usually increased 
in decompensated patients, are inversely correlated with 
abdominal fat, suggesting that this hormone may be involved 
in abdominal lipolysis.17,43
immunological activation
After the first report by Levine et al55 in 1990, showing that 
heart failure patients present increased tumor necrosis fac-
tor (TNF)-α serum levels, cardiac failure was considered as 
an immunologically activated disease. It was later verified 
in large trials such as SOLVD56 and VEST57 that TNF-α 
serum concentration is a good predictor of functional class, 
cardiac performance, and survival. These results were very 
important in understanding the physiopathology and systemic 
complications of heart failure. As well as TNF-α, other 
inflammatory cytokines such as IL-6, the IL-1 family, and 
anti-inflammatory cytokines such as IL-10 are also changed 
in heart failure.27,58
Several cells can secrete cytokines. During heart failure, 
the injured myocardium and skeletal myocytes can produce 
and release cytokines into the circulation.27 Cytokine synthe-
sis can be stimulated by several factors including hemody-
namic overload, neurohormonal activation, tissue hypoxemia 
and hypoperfusion, and, as previously reported, endotoxin-
like lipopolysaccharides.58 In experimental studies, increased 
TNF-α expression induces several deleterious effects; 
these include heart failure phenotype, endothelial dysfunc-
tion, erythropoiesis inhibition, gut permeability change, 
decreased free radical enzyme-removing activity, cachexia, 
and skeletal muscle changes such as apoptosis, proteolysis, 
atrophy, and functional alterations in   contractile proteins.59–61 
  Inflammatory cytokine-induced skeletal muscle changes 
have important consequences on inducing muscle wasting 
and cachexia.
Gastrointestinal abnormalities
The role of gastrointestinal system on cardiac cachexia has 
recently been studied in detail.62 Several structural changes 
have been described such as collagen accumulation and 
increased thickness of the intestine wall, which suggest 
bowel wall edema.63,64 These alterations increase the distance 
between capillary wall and enterocyte membrane and can 
impair both intestinal mucosa perfusion and gut   absorption.65 
Functional changes such as reduced protein and fat absorption 
and increased paracellular passive permeability have also been 
described.63,64 Additionally, increased bacteria concentration 
and the extent of their adherence to sigmoidal mucosal biofilm 
have been observed in heart failure.63 The combination of 
increased paracellular permeability and intestinal bacteria col-
onization can contribute to an increase in the gut permeability 
to bacterial endotoxin-like   lipopolysaccharides.51 This process 
is known as bacterial translocation.   Lipopolysaccharides are 
considered powerful inducers of TNF-α and other proin-
flammatory substances.27,59,66 Finally, as hepatic abnormali-
ties in heart failure are relatively common, they can impair 
the removal of bacterial endotoxins, thus contributing to 
immune   activation.67 All these data strongly suggest that heart 
failure-induced gastrointestinal abnormalities are involved 
in systemic inflammatory activation, cachexia, and muscle 
wasting.
Food intake reduction
Reduced food intake can be caused by anorexia, whose causal 
mechanisms are not completely clear. Several factors may 
be involved such as poor diet palatability due to low sodium 
content, severe depression, and passive visceral congestion. 
Drugs often used in treating heart failure can contribute to 
reduce food intake. Angiotensin-converting enzyme inhibi-
tors, particularly captopril, can change food taste and reduce 
food intake. Digitalis intoxication usually causes anorexia, 
nausea, and vomiting.51 Chronic and vigorous use of diuret-
ics can deplete body potassium, reducing intestinal motility, 
and zinc, changing food palatability.34 Inflammatory cytokine 
activation and abnormal leptin and adiponectin serum levels 
also cause anorexia.68
Heart failure patients also experience intrinsic distur-
bances in appetite regulation. The hypothalamus is the main 
site-regulating appetite. Several neuropeptides act on differ-
ent areas of the hypothalamus inducing appetite or satiety. 
It has been suggested in heart failure that satiety-inducing 
neuropeptides predominate over those leading to hunger and 
appetite.69 In fact, it was recently showed in mice that AII 
decreases food intake by suppressing hypothalamic expres-
sion of orexigenic neuropeptides.70
Other factors besides anorexia can also contribute to 
reduced food intake, including early satiety due to severe 
hepatomegaly, and reduced lipid intake, which is frequently 
recommended for coronary artery disease patients. A decrease 
in this dietary nutrient, which has a high energetic density, Research Reports in Clinical Cardiology 2014:5 submit your manuscript | www.dovepress.com
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may not be compensated for by a proportional increase in 
carbohydrate intake. Finally, it should be pointed out that, 
in functional class IV patients, resting dyspnea is a limiting 
factor for food intake.
Finally, an increase in resting energy expenditure seems 
not to be involved in body weight loss during heart failure. 
Recent studies have shown that cachectic patients do not 
present with significantly increased resting energy expen-
diture compared with noncachectic patients and healthy 
controls.71,72
Clinical consequences of cachexia
The clinical manifestations of cachexia are caused by both 
weight loss and systemic inflammation. In cachexia, there 
is a loss of tissue from three compartments: lean tissue, fat 
mass, and bones.17 As can be seen from the previous section, 
skeletal muscle wasting can be both a cause or a consequence 
of cachexia.26 Increased catabolism and body weight loss 
are also associated with a decrease in respiratory muscle 
strength.73
It was recently observed that fat mass wasting is also 
predictive of adverse outcome. It is not known whether fat 
loss is a surrogate of enhanced catabolism or adipose tissue 
is cardioprotective in the heart failure context.74,75
Severe body weight loss, even in the absence of sys-
temic inflammation, is associated with deleterious effects 
in most organs and systems, including changes in cardiac 
and gastrointestinal systems, anemia, reduced immunity, an 
increased risk of acquiring infections, alterations in respira-
tory function, reduced bone and muscle mass, decreased 
capacity to urinary concentration and acidification, reduced 
tissue healing, and a predisposition to pressure ulcers in 
bed rest patients.
It is not possible to determine the cardiac consequences 
of heart failure-induced cachexia as the heart is primar-
ily affected. Experimental studies have shown that cancer 
cachexia induces left ventricular dysfunction and molecu-
lar changes characteristic of the pathologic remodeling 
  process.50,76 In our laboratory, we evaluated the cardiac effects 
of severe food restriction in normotensive and hypertensive 
rats. Body weight reduction was associated with a reduction 
in heart mass. In normotensive animals, morphological, ultra-
structural, and functional myocardial changes were slight.77–82 
However, in the hypertrophied heart of hypertensive rats, 
structural changes were more severe and were combined 
with ventricular and myocardial systolic dysfunction.83–86 
Therefore, severe food restriction induces mild morpho-
logical and functional changes in normal hearts, which are 
exacerbated in hemodynamic overloaded hearts. In clinical 
setting, it was recently observed that left ventricular mass 
correlates with lean body mass in cachectic patients showing 
that the heart suffers similar consequences than lean tissue 
during cachexia.87
Cachexia can exacerbate heart failure-associated 
gastrointestinal changes by inducing enterocyte atrophy, 
reducing gut villi, and increasing the risk of bacterial 
translocation.62
Finally, anemia, a frequent complication of heart failure, 
can also be impaired by cachexia. Although anemia etiology 
is multifactorial, cachexia-related factors such as reduced 
intestinal absorption and chronic inflammation contribute 
to its physiopathology. Iron deficiency has been reported 
in variable frequency during heart failure ranging from 1% 
to 44%, depending on case severity.88,89 Iron deficiency not 
only impairs erythropoiesis but also dilates the left ventricle, 
induces cardiac ultrastructural and mitochondrial changes, 
impairs cardiac function, stimulates the sympathetic ner-
vous system, causes thrombocytosis, and impairs quality 
of life.90,91
Treatment perspectives
The multifactorial pathogenesis of these conditions has 
complicated the development of specific therapy for heart 
failure-induced cachexia and muscle wasting.92 Different 
treatment options have been described, mostly evaluated only 
in experimental settings or in small clinical studies. Currently, 
nonpharmacological therapy as nutritional support and physical 
exercise is considered the basis for treating these conditions.93 
It is important to point out that an increase in food intake may 
compensate some weight loss, but it can cause a shift in tis-
sue distribution, particularly when muscle loss is present.92 
  Therefore, nutritional support should be combined with exer-
cise training in order to preserve or recover muscle mass. In 
fact, exercise training has been considered the most promising 
option for treating muscle wasting in several diseases.93 Table 1 
shows a schematic description of potential therapeutic options 
for patients with cardiac cachexia and muscle wasting.
In conclusion, cardiac-associated cachexia and muscle 
wasting are multifactorial conditions that contribute to 
increased morbidity and mortality in heart failure. A bet-
ter understanding of the mechanisms involved in their 
physiopathology will hopefully lead to the development of 
pharmacological and nonpharmacological therapies to effec-
tively prevent and treat heart failure-induced cachexia and 
muscle wasting before significant body weight and muscle 
wasting occurs.Research Reports in Clinical Cardiology 2014:5 submit your manuscript | www.dovepress.com
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